Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 9/20 | 0.39 |
| ▸ | JAK1 | P23458 | 7/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99841 | 0.91 | GRM4 (0.57) | GRM4PRKCIAURKBAURKAINCENP | |
| Trifluoroacetic Acid SCHEMBL4086462 | 0.89 | GRM4 (0.58) | GRM4AURKBAURKAINCENPTPX2 | |
| Trifluoroacetic Acid SCHEMBL4092318 | 0.88 | GRM4 (0.48) | GRM4PRKCIAURKBAURKAINCENP | |
| Trifluoroacetic Acid SCHEMBL4082067 | 0.85 | PRKCI (0.54) | GRM4PRKCIAURKBAURKAINCENP | |
| Trifluoroacetic Acid SCHEMBL4097029 | 0.84 | GRM4 (0.52) | GRM4PRKCIAURKBAURKAINCENP | |
| Trifluoroacetic Acid SCHEMBL4086835 | 0.84 | PRKCI (0.48) | GRM4PRKCIAURKBAURKAINCENP | |
| Trifluoroacetic Acid SCHEMBL4088293 | 0.83 | GRM5 (0.47) | GRM4PRKCIJAK2JAK1EGLN1 | |
| Trifluoroacetic Acid SCHEMBL4088934 | 0.82 | PRKCI (0.46) | GRM4PRKCIAURKBAURKAJAK2 | |
| Trifluoroacetic Acid SCHEMBL4088095 | 0.81 | GRM4 (0.50) | GRM4AURKBAURKAINCENPTPX2 | |
| Trifluoroacetic Acid SCHEMBL14973936 | 0.81 | GRM4 (0.47) | GRM4PRKCIAURKBAURKAINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | GRM4 2958/4885PRKCI 304/4885AURKB 198/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | GRM4 2958/4885PRKCI 304/4885AURKB 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.